Delving into the Latest Updates on siAKR1C3@PPA with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms-

Target

Mechanism

17β-HSD5 inhibitors(Aldo-keto-reductase family 1 member C3 inhibitors), PSMA modulators(Prostate-specific membrane antigen modulators)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Castration-Resistant Prostatic Cancer

Inactive Indication-

Originator Organization

Jilin University

Active Organization

Jilin University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

IntroductionAKR1C3, as a crucial androgenic enzyme, implicates the androgen biosynthesis and promoting prostate cancer cell growth in vitro. This study provides a new gene therapy strategy for targeting AKR1C3 to treat castration-resistant prostate cancer.MethodssiAKR1C3@PPA is assembled from PEG3500, PAMAM, Aptamer-PSMA, and siRNA for AKR1C3. We analyzed the relationship between AKR1C3 expression and the survival rate of prostate cancer patients based on the GEPIA online database to perform disease-free survival, and found that AKR1C3 may be an important factor leading to poor prognosis in prostate cancer. Considering AKR1C3 as a therapeutic target for castration-resistant prostate cancer, we constructed a complex nucleic acid nanoparticle, siAKR1C3@PPA to investigate the inhibitory effect on castration-resistant prostate cancer.ResultsAptamer-PSMA acts as a target to guide siAKR1C3@PPA into PSMA-positive prostate cancer cells and specifically down regulate AKR1C3. Cyclin D1 was decreased as a result of siAKR1C3@PPA treatment. Changes in Cyclin D1 were consistent with decreased expression of AKR1C3 in LNCaP-AKR1C3 cells and 22RV1 cells. Furthermore, in the LNCaP-AKR1C3 group, 1070 proteins were upregulated and 1015 proteins were downregulated compared to the LNCaP group according to quantitative 4D label-free proteomics. We found 42 proteins involved in cell cycle regulation. In a validated experiment, we demonstrated that PCNP and CINP were up-regulated, and TERF2 and TP53 were down-regulated by western blotting.ConclusionWe concluded that siAKR1C3@PPA may arrest the cell cycle and affect cell proliferation.

100 Deals associated with siAKR1C3@PPA

Login to view more data